Calcium-D-Glucarate for Health & Longevity - Quick Reference Sheet

Calcium-D-Glucarate for Health & Longevity

Created on 07/17/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 4.8 Audit

A low-cost supplement that aims to help the body clear used hormones and unwanted substances more fully by slowing an enzyme that would otherwise let them return. Laboratory and animal work shows lower hormone levels and less tumor formation, but human proof is missing. Safety is gentle; the main caution is faster removal of some medicines, including birth control. (Full Review)

Protocol

Standard Dose
500–1,500 mg/day
up to 3,000 mg/day in some hormone-focused protocols
Frequency
Split 2–3×/day
maintains more continuous enzyme inhibition
Timing
With meals
doses divided across the day
Time to effect
Hormone Effects
Weeks
estrogen changes unfold gradually
Reassessment
8–12 weeks
recheck estrogen markers
Acute Effect
None
no immediate, perceptible change

Benefits

Contraindications
  • Pregnancy and breastfeeding
  • Clinically low estrogen
Key Interactions
  • Glucuronidated medications (oral contraceptives, estrogen therapy, tamoxifen and other SERMs, benzodiazepines, opioids, mycophenolate, lamotrigine)
  • Acetaminophen (paracetamol)
  • Additive estrogen-lowering supplements (DIM, indole-3-carbinol, sulforaphane, milk thistle)
  • Estrogen-lowering cancer therapy (aromatase inhibitors, SERMs)

Risk & Side Effects

  • High:
  • Medium:
  • Low: Increased clearance of glucuronidated drugs and hormones; gastrointestinal upset
  • Speculative: Excessive lowering of estrogen; added calcium at high doses

Monitoring

Marker Target Why
Estradiol (E2) Premenopausal ~30–200 pg/mL; men ~10–40 pg/mL Primary target hormone the compound aims to help clear
Estrone (E1) ~30–100 pg/mL Secondary estrogen affected by recirculation
SHBG ~40–80 nmol/L (women); ~20–60 nmol/L (men) Governs how much estrogen is free and active
LDL cholesterol < 100 mg/dL Tracks the possible lipid-lowering effect seen in animals
GGT < 20–25 U/L Liver-clearance and oxidative-stress marker
Urinary D-glucaric acid No standardized optimal target Validated marker of glucuronidation/detoxification activity

Cadence: Estrogen markers at 8–12 weeks, then every 6–12 months if continued; lipid and liver markers every 6–12 months

Qualitative Assessment

  • Cyclical breast tenderness and premenstrual symptom severity
  • Menstrual regularity and cycle-related mood changes
  • General energy and sense of well-being
  • Any digestive side effects signaling a need to lower the dose